Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 10/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683008 | 0.74 | PDE4B (0.47) | JAK3JAK1HSP90AA1HSP90AB1 | |
| SCHEMBL27701122 | 0.72 | NNMT (0.42) | JAK2ALDH1A1 | |
| SCHEMBL12289243 | 0.69 | ALDH1A1 (0.49) | JAK2ROCK2BTKALDH1A1 | |
| SCHEMBL28455285 | 0.68 | CYP3A4 (0.40) | SYKALDH1A1HSP90AA1 | |
| SCHEMBL27622038 | 0.68 | IKBKB (0.43) | BTK | |
| SCHEMBL354227 | 0.66 | SIRT3 (0.45) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL12493699 | 0.65 | JAK2 (0.79) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL29212433 | 0.65 | CA12 (0.34) | SYKALDH1A1 | |
| Hydrochloric Acid SCHEMBL1776795 | 0.64 | SIRT3 (0.44) | ALDH1A1 | |
| SCHEMBL25436217 | 0.63 | SIRT3 (0.37) | BTKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101010309-A | Oxopiperidine derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-08-01 | — | — | CN | disclosed |